Alain CornetStene Prize Every year EULAR and the Standing Committee of PARE offer the Edgar Stene Prize for the best essay on a previously determined topic. The winner receives a prize money of EUR 1,000 is awarded during the Opening Plenary Session at the Annual EULAR Congress and is invited to the congress dinner. In addtion, […]
Alain CornetSAVE THE DATE 2nd EULAR Young PARE youth meeting Friday 21 October – Sunday 23 October 2016 Corsendonke de Linde, Retie, Belgium This email serves for you to block the dates in your calendar, for when our 2nd EULAR Young PARE youth meeting will take place. The location is Corsendonke de Linde, Retie, Belgium. Please share this email with […]
Alain CornetHere is a video featuring Claudine Goyens (who has also written a patient story for LUPUS EUROPE) who encourages us to submit our story for World Arthritis Day. For more information on World Arthritis Day and the stories, please click here. The deadline for submission of stories is 29th July 2016.
Alain CornetHere is an overview of the common World Lupus Day campaign compiled by the World Lupus Federation on the extent and spread of the joint World Lupus Day Campaign. Duane Peters, who has been coordinating the WLF campaign, has told us that the response received has been excellent, especially the results of social media efforts. News about the […]
Alain CornetAs part of our initiatives directed towards youth, trustee Jeanette Andersen, who is responsible for youth related work, has set up a LUPUS EUROPE YOUTH group on facebook. Here is what she has to say about the group. “A group for all young people (aged 18-35) with lupus in Europe. Whether you have a youth group […]
Alain CornetHere is a video extract from an interview with Anne Charlet, vice-chair LUPUS EUROPE, speaking to MedTech about her daughter living with lupus. [youtube https://www.youtube.com/watch?v=eeF5or2K168&w=560&h=315] You can see Anne’s full World Lupus Day interview here.
✅ If you have #LUPUS 🦋 or #Sjogren & #FATIGUE please try #LEAF our #digital research tool 📲 and get a (free) PERSONALIZED feedback about your #FATIGUE 👍
➡️ English:
https://iamfatigued.limequery.org/584745?lang=en
➡️ Español: https://iamfatigued.limequery.org/584745?lang=es
➡️ Français: https://iamfatigued.limequery.org/584745?lang=fr
📢 Online first
"Perioperative management of disease-modifying antirheumatic drugs and other immunomodulators"
🔗
☑️ cDMARDs can be continued;
☑️ tsDMARDs should be suspended at least 3-7 days before surgery:
☑️ bDMARDs should be withheld a dosing cycle
ARP Rheumatology
Objectives: We aim to summarize the relevant evidence and provide guidance for perioperative management of disease-modif...
arprheumatology.com
🆒 How does TREAT-to-TARGET 🎯 apply to #LUPUS? 🦋
How do you achieve #REMISSION?
Is #LLDAS a good "plan B"? 🥊
Can you descalate #SLE #TREATMENT 💊 including glucocorticoids ?
🔎⬇️
🆕 I've been asked about Undifferentiated Connective Tissue Disease (#UCTD). In the first 5y following the diagnosis:
➡️ 65-70% remain UCTD
➡️ 10-15% get into remission
➡️ 20-30% fullfill criteria for a defined CTD, mostly RA & #Lupus
Check ✅ the diagram below for changes 👍
📢 Participate in #StenePrize2023 competition!
⭐ Share your story on the topic: How has better communication with your doctor improved your life with an #RMD?
Submit your essay through a EULAR PARE national member organisation 👉 https://bit.ly/2Xoyv8X.
#eularPARE #EULAR
Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the @NEJM
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus | NEJM
Original Article from The New England Journal of Medicine — Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
buff.ly
🆕🔥British Society for Rheumatology (BSR): guideline on prescribing drugs in pregnancy and breastfeeding
Draft Guidelines available for review
Short Summary
https://www.rheumatology.org.uk/practice-quality/guidelines
Delighted to share our Editorial for @RheumJnl on plasmablast immunometabolism is #SLE 🧫 🧪
Huge thanks to @SerenaFasanoSLE for writing this with me! 👏🏻 🙏🏻 ⭐️
💻 Link to Editorial - https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keac418/6647836
💻 Link to Original Article - https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/keac338/6605851
@ImmunoMet
🆒 Following my previous tweet 🔄 about the MOST IMPORTANT patterns ✅ of antinuclear antibodies (#ANA) in #autoimmune diseases, here is a list 📃of those TYPICAL for #Lupus 🦋 including anti-dsDNA (60-80%) & anti-Sm (10-30%, based on ethnicity) 👍
#Medtwitter #RheumTwitter
A call to all neurologists,psychiatrists, rheumatologists & other clinicians involved in the care of rheumatology patients! Please complete this important survey on neuropsychiatric symptoms & clinician-patient relationships from @Cambridge_Uni. Thank you! https://bit.ly/inspire_clinicians
🆒 Nicely done 👍⬇️
Immune monitoring and treatment in #immune-mediated #inflammatory diseases by Wijk et al. Nat Commun 2022
Link: https://doi.org/10.1038/s41467-022-30891-7
The 13th European Lupus Meeting 2022 wants to provide the best care to his patients, who can actively participate in our Congress!
Sign up in large numbers, your fee remains unchanged at 50 Euros until the onsite registration: https://bit.ly/3QXwTwa
@LupusEurope
#SLEuro
Thank you all for participating in the INSPIRE study by @Cambridge_Uni! To fully represent the patient voice,we still need more participants!Especially men.
This is a very important study as it could make an impact on the health services & quality of life https://bit.ly/inspire_patients
🚨 Just published in the @NEJM
Phase 2 trial of anti-BDCA2 Antibody #Litifilimab for Cutaneous #Lupus Erythematosus 🦋 At W16, the difference from placebo in the change from baseline in CLASI-A score was significant in all 3 dosages of Litifilimab 👍
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus | NEJM
Original Article from The New England Journal of Medicine — Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
www.nejm.org
@LupusEurope @chriswincup Here is the evidence 🔎 👍
#Glucocorticoid tapering in #Lupus
#pregnancy #rheumaticdiseases 🤰🤱👶
Watch the #EULAR2022 Insight 👇🏻
Italian Pregnancy Registry http://P-RHEUM.it 🇮🇹
🆕 Post-partum #depression screening by #EPDS ➡️ 1 out of 10 women had at-risk score
Need to address this issue and offer support to our patients 🆘 https://twitter.com/SerenaFasanoSLE/status/1549431145355419650
EULAR 2022 Insight https://youtu.be/duSWsx8_ZzE Delighted to share this special interview with Prof Laura Andreoli, from #EULAR2022.
I was inspired to hear about her pregnancy project in rheumatic diseases. Hope you enjoy 😊#EULARTV @lauraandreoli80
@LupusEurope @chriswincup The data discussed in the interview are highly controversial and have been contradicted by newer data on a longer term basis. The general and largely agreed upon idea is that, if possible, #glucocorticoids should be tapered and stopped in systemic #Lupus.
Steroids are one of the most common treatments in lupus. What dose should rheumatologists aim for when #lupus is in remission?
Is it possible to withdraw steroids?
Find all the answers in this interview by @chriswincup to Prof. Amoura
🆕 #EULARTVondemand "EULAR 2022 Insight" with Prof. Amoura.
Watch the complete interview 👉 https://youtu.be/tJAbm3TSQrE
⭐ Login to access the #EULAR2022ondemand until 31 July! https://bit.ly/3yJU8lW
#EULAR2022 #EULARTV
According to this study carried out in several centres in Italy and presented by Prof. @lauraandreoli80 in the @eular_org congress:
- Pregnancy outcomes are good in women with MRDs.
- 90% life births achieved.
- 7% flares.
Always talk to your physician before trying to conceive!
EULAR 2022 Insight https://youtu.be/duSWsx8_ZzE Delighted to share this special interview with Prof Laura Andreoli, from #EULAR2022.
I was inspired to hear about her pregnancy project in rheumatic diseases. Hope you enjoy 😊#EULARTV @lauraandreoli80
Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the The New England Journal of Medicine, which you can find in the "Info Centre" section of our website!
Don't forget to subscribe to be up to date!
www.lupus-europe.org/me-lupus/lupus-europe-info-centre/
No matter what chronic illness you're living with, having a sense of community and knowing
that you're not alone is helps your daily health and is key to staying motivated.
Follow the community over at @ThisIsLivingToday for tips and advice on wellness, mindfulness and movement. Let’s fight the daily battle together.
We have partnered with @ThisIsLivingToday, a community of people living with chronic conditions with the aim of sharing tips, advice and inspirational stories that help improve health. 🧡
Follow their page @ThisIsLivingToday and hear from individuals who are facing the same challenges you may be facing. Let’s work together and lift each other up.
Good news!!! Belimumab, a monoclonal antibody, has been approved by the FDA for the treatment of pediatric patients with active lupus nephritis on standard therapy.
Belimumab is the first treatment specifically approved for lupus in more than 50 years.
You can read more about it, plus the results of the phase II, in the link from MedPage Today 👇
www.medpagetoday.com/rheumatology/lupus/99927
💜
Yes!!!!!!
nu hopen dat Nederland artsen dit overneemt🤔
So happy to hear this
Brilliant
